February 2016 Vol 9, No 1

ICER is a Boston-based independent nonprofit organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures. The organization represents perhaps the first major US attempt to complete and publicly share comprehensive health technology assessments.
The US healthcare system is broken financially and quality-wise. The present financing system is not sustainable; nearly 20% of the US gross domestic product is spent on healthcare.
Time to Reexamine Accountable Care Organizations?
Breast cancer, the most common malignancy in women in the United States, is a serious disease associated with substantial medical and economic burden.
An Ounce of Prevention Is Not a Choice a Patient Gets to Make for Late-Stage Cancer
The new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors can have significant budget effects, depending on the breadth of the US Food and Drug Administration (FDA)’s approved labeling. American Health & Drug Benefits asked Stephen Gorshow, MD, and James T. Kenney, RPh, MBA, to participate in a teleconference to better understand how payers are approaching the management of these agents.
Many of the 2016 healthcare trends began between 2012 and 2014 and finally emerged more clearly in 2015 for commercially insured populations.
Major pharmaceutical companies currently devote substantial resources to detailing activities for their major products, with estimated annual spending of $7 billion to $20 billion.
Improving Patient Outcomes and Drug Prescribing Cost-Effectiveness Through Academic Detailing

Results 1 - 6 of 6
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME